Breaks Categories: News

MondayAug 11, 2025 9:10 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Q2 2025 Results and Business Highlights

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted therapies to deliver genetic medicines to metastatic disease sites, reported a Q2 2025 net loss of $5.7 million, or $1.99 per share, compared to a net loss of $7.4 million, or $16.75 per share, in Q2 2024. R&D expenses were $2.6 million versus $2.2 million last year, while G&A expenses were $3.1 million compared to $3.6 million. Calidi ended the quarter with $5.3 million in cash and $0.1 million in restricted cash. Recent highlights include new preclinical data on CLD-401 from the proprietary RedTail platform, showing enhanced efficacy through…

Continue Reading

FridayAug 08, 2025 10:55 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics(TM) Secures Florida Regulatory Clearance to Close Dura Medical Acquisition

NRx Pharmaceuticals (NASDAQ: NRXP), through its wholly owned subsidiary HOPE Therapeutics(TM), Inc., announced it has received final clearance from the Florida Agency for Health Care Administration to proceed with closing its acquisition of revenue-generating, EBITDA-positive Dura Medical LLC, pending customary conditions. Founded in 2018, Dura operates clinics on Florida’s west coast specializing in mental health and chronic pain treatment, offering Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), Spravato(R), Stellate Ganglion Blocks, and Traumatic Incident Reduction Therapy. The company also serves veterans through the Veterans Affairs Community Cares Network. HOPE leaders said the acquisition will expand its Florida network and integrate…

Continue Reading

FridayAug 08, 2025 9:30 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures FDA Type C Meeting for AVERSA(TM) Fentanyl Abuse-Deterrent Patch

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the U.S. Food and Drug Administration has granted a Type C Meeting on Sept. 18, 2025, to review Chemistry, Manufacturing, and Controls plans for its lead product, AVERSA(TM) Fentanyl. Developed in partnership with Kindeva, the patch integrates Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch to help prevent abuse, diversion, misuse, and accidental exposure while maintaining access for patients in need. Positioned to be the world’s first abuse-deterrent opioid patch, AVERSA Fentanyl targets peak annual U.S. sales potential of $80 million to $200 million, with future global market expansion…

Continue Reading

ThursdayAug 07, 2025 12:02 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured in NNW Editorial on Rare Disease Innovation

Soligenix (NASDAQ: SNGX) today announced its inclusion in a NetworkNewsWire ("NNW") editorial titled “Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators.” The article underscores the growing healthcare challenges of rare diseases among aging Americans and the urgent need for effective therapies. Soligenix is spotlighted for its HyBryte(TM) platform, a novel treatment for cutaneous T-cell lymphoma (CTCL), a rare skin cancer primarily affecting older adults. With U.S.-based manufacturing now established for HyBryte’s active ingredient, Soligenix demonstrates a commitment to domestic innovation and support for underserved patient populations. To view the full press release, visit https://ibn.fm/4UuJW About Soligenix Inc.…

Continue Reading

ThursdayAug 07, 2025 9:50 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Launches Multilingual Podcast to Raise Awareness of Breast Imaging Innovation

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging technologies for breast cancer detection, has launched a multilingual podcast series titled Beyond the Mammogram: Rethinking the Future of Breast Imaging. Available in seven languages, the series aims to inform global audiences about limitations in current imaging tools and the need for more accurate technologies like Izotropic’s IzoView Breast CT system. The podcast repurposes public data into educational content for patients, professionals, and stakeholders as the Company moves toward regulatory approval. To view the full press release, visit https://ibn.fm/ba9ZT About Izotropic More information about Izotropic Corporation can…

Continue Reading

WednesdayAug 06, 2025 12:09 pm

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial

Lantern Pharma (NASDAQ: LTRN) announced that its wholly owned subsidiary, Starlight Therapeutics, has received FDA clearance for an Investigational New Drug (“IND”) application to initiate a Phase Ib/2a clinical trial of STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (“GBM”) at first progression. The study will evaluate safety, tolerability and preliminary efficacy in recurrent GBM, a highly aggressive brain cancer with limited treatment options. STAR-001 is a brain-penetrant DNA-damaging agent designed to exploit DNA repair deficiencies through synthetic lethality, and its effect is enhanced by spironolactone, which induces NER deficiency in tumor cells. The therapy has received…

Continue Reading

WednesdayAug 06, 2025 9:20 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) to Report Q2 2025 Financial Results on August 14

NextPlat (NASDAQ: NXPL, NXPLW) a global provider of healthcare and technology solutions, will release its financial results for the quarter ended June 30, 2025, before market open on August 14. A conference call hosted by Interim CEO David Phipps and CFO Cecile Munnik will follow at 8:30 a.m. EDT to review the results and discuss recent developments. To view the full press release, visit: https://ibn.fm/5jNo9 About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in…

Continue Reading

TuesdayAug 05, 2025 12:25 pm

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Market Demand for Breast CT Imaging Innovation 

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) emphasized the global trends driving demand for advanced breast cancer imaging technologies and the advantages of its IzoView Breast CT Imaging System. With over 2.3 million new cases of breast cancer diagnosed worldwide annually and U.S. incidence projected to exceed 315,000 in 2025, healthcare systems face growing pressure to improve screening outcomes. Market forecasts show global breast imaging revenues rising from $5.4 billion in 2024 to $8.69 billion by 2030. IzoView addresses clinical and patient needs with non-compressive 3D imaging, offering a more comfortable, accurate, and scalable alternative to conventional modalities—especially for the…

Continue Reading

TuesdayAug 05, 2025 12:03 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Canaccord 45th Annual Growth Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases such as ALS and MS, announced that its management will present at the Canaccord 45th Annual Growth Conference and participate in one-on-one investor meetings. To view the full press release, visit https://ibn.fm/NAgsD About Clene Inc. Clene Inc., (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central…

Continue Reading

TuesdayAug 05, 2025 9:36 am

BioMedNewsBreaks — Soligenix, Inc. (NASDAQ: SNGX) Spotlighted in Editorial on Rare Disease Therapeutics 

Soligenix (NASDAQ: SNGX) has been featured in a NetworkNewsWire editorial highlighting its progress in addressing rare diseases, particularly among aging populations. The piece emphasizes the urgent need for effective treatments as over 30 million Americans live with rare conditions, many lacking FDA-approved therapies. Soligenix’s HyBryte(TM) platform, targeting cutaneous T-cell lymphoma—a rare skin cancer affecting older adults—represents a promising solution. With successful domestic manufacturing of HyBryte’s active ingredient, the company advances its mission to serve this underserved demographic with innovative, U.S.-based therapies. To view the full press release, visit https://ibn.fm/9qnqm About Soligenix, Inc. Soligenix is a late-stage biopharmaceutical company focused on…

Continue Reading